S&P 500   4,584.47 (+0.77%)
DOW   36,092.99 (+0.11%)
QQQ   390.21 (+1.34%)
AAPL   194.73 (+1.25%)
MSFT   370.29 (+0.40%)
META   327.40 (+3.13%)
GOOGL   137.66 (+5.88%)
AMZN   147.07 (+1.76%)
TSLA   242.17 (+1.17%)
NVDA   462.74 (+1.69%)
NIO   7.47 (-3.61%)
BABA   72.18 (+0.97%)
AMD   124.90 (+6.92%)
T   17.07 (+0.77%)
F   10.81 (+1.12%)
MU   73.57 (+0.60%)
CGC   0.72 (+3.57%)
GE   118.49 (-1.10%)
DIS   92.86 (+1.49%)
AMC   6.84 (+0.74%)
PFE   28.70 (-0.31%)
PYPL   58.23 (-2.18%)
XOM   98.79 (-0.32%)
S&P 500   4,584.47 (+0.77%)
DOW   36,092.99 (+0.11%)
QQQ   390.21 (+1.34%)
AAPL   194.73 (+1.25%)
MSFT   370.29 (+0.40%)
META   327.40 (+3.13%)
GOOGL   137.66 (+5.88%)
AMZN   147.07 (+1.76%)
TSLA   242.17 (+1.17%)
NVDA   462.74 (+1.69%)
NIO   7.47 (-3.61%)
BABA   72.18 (+0.97%)
AMD   124.90 (+6.92%)
T   17.07 (+0.77%)
F   10.81 (+1.12%)
MU   73.57 (+0.60%)
CGC   0.72 (+3.57%)
GE   118.49 (-1.10%)
DIS   92.86 (+1.49%)
AMC   6.84 (+0.74%)
PFE   28.70 (-0.31%)
PYPL   58.23 (-2.18%)
XOM   98.79 (-0.32%)
S&P 500   4,584.47 (+0.77%)
DOW   36,092.99 (+0.11%)
QQQ   390.21 (+1.34%)
AAPL   194.73 (+1.25%)
MSFT   370.29 (+0.40%)
META   327.40 (+3.13%)
GOOGL   137.66 (+5.88%)
AMZN   147.07 (+1.76%)
TSLA   242.17 (+1.17%)
NVDA   462.74 (+1.69%)
NIO   7.47 (-3.61%)
BABA   72.18 (+0.97%)
AMD   124.90 (+6.92%)
T   17.07 (+0.77%)
F   10.81 (+1.12%)
MU   73.57 (+0.60%)
CGC   0.72 (+3.57%)
GE   118.49 (-1.10%)
DIS   92.86 (+1.49%)
AMC   6.84 (+0.74%)
PFE   28.70 (-0.31%)
PYPL   58.23 (-2.18%)
XOM   98.79 (-0.32%)
S&P 500   4,584.47 (+0.77%)
DOW   36,092.99 (+0.11%)
QQQ   390.21 (+1.34%)
AAPL   194.73 (+1.25%)
MSFT   370.29 (+0.40%)
META   327.40 (+3.13%)
GOOGL   137.66 (+5.88%)
AMZN   147.07 (+1.76%)
TSLA   242.17 (+1.17%)
NVDA   462.74 (+1.69%)
NIO   7.47 (-3.61%)
BABA   72.18 (+0.97%)
AMD   124.90 (+6.92%)
T   17.07 (+0.77%)
F   10.81 (+1.12%)
MU   73.57 (+0.60%)
CGC   0.72 (+3.57%)
GE   118.49 (-1.10%)
DIS   92.86 (+1.49%)
AMC   6.84 (+0.74%)
PFE   28.70 (-0.31%)
PYPL   58.23 (-2.18%)
XOM   98.79 (-0.32%)

Certara Stock Price, News & Analysis (NASDAQ:CERT)

$15.76
+0.13 (+0.83%)
(As of 12:15 PM ET)
Compare
Today's Range
$15.33
$15.80
50-Day Range
$12.12
$15.63
52-Week Range
$11.81
$24.96
Volume
436,211 shs
Average Volume
1.00 million shs
Market Capitalization
$2.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.71

Certara MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
25.2% Upside
$19.38 Price Target
Short Interest
Healthy
4.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.80mentions of Certara in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$747,870 Sold Last Quarter
Proj. Earnings Growth
-9.09%
From $0.33 to $0.30 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

223rd out of 958 stocks

Health Information Services Industry

5th out of 7 stocks


CERT stock logo

About Certara Stock (NASDAQ:CERT)

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, the Netherlands, the Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

CERT Stock Price History

CERT Stock News Headlines

Certara (NASDAQ:CERT) Now Covered by KeyCorp
Henry Ford Would NEVER Have Seen This Coming
In 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.
Q3 2023 Certara Inc Earnings Call
Henry Ford Would NEVER Have Seen This Coming
In 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.
Certara, Inc. (CERT) Q3 Earnings Meet Estimates
Certara Reports Third Quarter 2023 Financial Results
Circling Back On Certara
Robert W. Baird Reaffirms Their Hold Rating on Certara (CERT)
Certara Inc.
What Is Certara, Inc.'s (NASDAQ:CERT) Share Price Doing?
Berenberg Bank Keeps Their Buy Rating on Certara (CERT)
See More Headlines
Receive CERT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Certara and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/06/2024

Industry, Sector and Symbol

Industry
Health Information Services
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CERT
Fax
N/A
Employees
1,150
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.38
High Stock Price Target
$24.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+26.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
10 Analysts

Profitability

Net Income
$14.73 million
Pretax Margin
-11.06%

Debt

Sales & Book Value

Annual Sales
$352.96 million
Cash Flow
$0.69 per share
Book Value
$6.76 per share

Miscellaneous

Free Float
155,689,000
Market Cap
$2.50 billion
Optionable
Not Optionable
Beta
1.57
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. William F. Feehery Ph.D. (Age 52)
    CEO & Director
    Comp: $1.35M
  • Mr. Leif E. Pedersen (Age 58)
    President & Chief Commercial Officer
    Comp: $625.53k
  • Dr. Robert P. Aspbury Ph.D. (Age 51)
    President of Certara Scientific Software
    Comp: $518.09k
  • Dr. Patrick F. Smith Pharm.D. (Age 52)
    President of Drug Development Solutions
    Comp: $621.58k
  • Mr. John E. Gallagher III (Age 50)
    Chief Financial Officer
  • Mr. Max Kanevsky
    Chief Technology Officer
  • Prof. Amin Rostami PharmD
    Ph.D., FCP, Chief Scientific Officer
  • Mr. Richard M. TraynorMr. Richard M. Traynor (Age 51)
    Senior VP, General Counsel & Secretary
  • Mr. Ron DiSantis
    Senior Vice President of Corporate Development
  • Ms. Sheila Rocchio MBA
    Chief Marketing Officer














CERT Stock Analysis - Frequently Asked Questions

Should I buy or sell Certara stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Certara in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CERT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERT, but not buy additional shares or sell existing shares.
View CERT analyst ratings
or view top-rated stocks.

What is Certara's stock price target for 2024?

10 brokers have issued 12 month price targets for Certara's stock. Their CERT share price targets range from $16.00 to $24.00. On average, they predict the company's stock price to reach $19.38 in the next year. This suggests a possible upside of 25.2% from the stock's current price.
View analysts price targets for CERT
or view top-rated stocks among Wall Street analysts.

How have CERT shares performed in 2023?

Certara's stock was trading at $16.07 on January 1st, 2023. Since then, CERT stock has decreased by 3.7% and is now trading at $15.48.
View the best growth stocks for 2023 here
.

Are investors shorting Certara?

Certara saw a decrease in short interest in November. As of November 15th, there was short interest totaling 4,690,000 shares, a decrease of 11.0% from the October 31st total of 5,270,000 shares. Based on an average daily trading volume, of 677,600 shares, the short-interest ratio is currently 6.9 days. Approximately 4.3% of the company's shares are short sold.
View Certara's Short Interest
.

When is Certara's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our CERT earnings forecast
.

How were Certara's earnings last quarter?

Certara, Inc. (NASDAQ:CERT) posted its quarterly earnings data on Wednesday, November, 8th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by $0.02. The company had revenue of $85.58 million for the quarter, compared to analyst estimates of $85.96 million. Certara had a positive trailing twelve-month return on equity of 5.38% and a negative net margin of 9.56%.

What guidance has Certara issued on next quarter's earnings?

Certara issued an update on its FY23 earnings guidance on Wednesday, November, 8th. The company provided earnings per share guidance of $0.44-0.48 for the period, compared to the consensus EPS estimate of $0.45. The company issued revenue guidance of $345-360 million, compared to the consensus revenue estimate of $353.75 million.

When did Certara IPO?

(CERT) raised $500 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 24,400,000 shares at a price of $19.00-$22.00 per share. Jefferies, Morgan Stanley, BofA Securities, Credit Suisse, Barclays and William Blair acted as the underwriters for the IPO.

Who are Certara's major shareholders?

Certara's stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (5.75%), William Blair Investment Management LLC (4.48%), Clearbridge Investments LLC (2.58%), JPMorgan Chase & Co. (2.44%), Riverbridge Partners LLC (1.65%) and Massachusetts Financial Services Co. MA (1.32%). Insiders that own company stock include Avatar Parent LP Eqt, Craig R Rayner, Eran Broshy, James E Cashman III, Jieun W Choe, Justin Edge, Leif E Pedersen, Mason P Slaine, Matthew M Walsh, Michael Andrew Schemick, Patrick F Smith, Richard M Traynor, Robert Aspbury, Stephen M Mclean and William F Feehery.
View institutional ownership trends
.

How do I buy shares of Certara?

Shares of CERT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CERT) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -